Verve Therapeutics Income Statement

Financials in millions TRY. Fiscal year is January - December.

Millions TRY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,049	1,115	1,422	1,396	924.17
Revenue Growth (YoY)	-24.88%	-21.63%	1.87%	51.07%	-
Cost of Revenue	911.39	929.96	1,047	981.87	687.73
Gross Profit	137.47	184.64	375.04	414.28	236.44
Selling, General & Admin	233.93	222.57	224.31	137.79	91.85
Research & Development	0.46	0.43	-	-	-
Other Operating Expenses	-48.09	-49.52	-22.34	-5.74	-8.36
Operating Expenses	186.3	173.48	201.97	132.05	83.49
Operating Income	-48.83	11.16	173.08	282.22	152.95
Interest Expense	-33.63	-31.94	-54.94	-67.92	-60.31
Interest & Investment Income	42.69	17.48	58.11	4.68	8.36
Currency Exchange Gain (Loss)	0.01	-0.5	-8.94	-9.72	2.13
Other Non Operating Income (Expenses)	-28.79	-24.56	73.95	107.83	59.7
EBT Excluding Unusual Items	-68.56	-28.35	241.26	317.09	162.84
Gain (Loss) on Sale of Investments	-1.37	-1.34	-18.9	-12.54	-43.52
Legal Settlements	-0.59	-0.59	-2.18	-0.5	-0.25
Other Unusual Items	-	-	-1.06	-	-
Pretax Income	-70.53	-30.23	219.58	306.97	119.83
Income Tax Expense	-81.98	-4.63	17.77	30.5	-144.76
Net Income	11.45	-25.6	201.81	276.47	264.59
Net Income to Common	11.45	-25.6	201.81	276.47	264.59
Net Income Growth	-95.86%	-	-27.00%	4.49%	-
Shares Outstanding (Basic)	101	100	43	32	32
Shares Outstanding (Diluted)	101	100	43	32	32
Shares Change (YoY)	216.19%	130.77%	35.42%	-	-
EPS (Basic)	0.11	-0.26	4.66	8.64	8.27
EPS (Diluted)	0.11	-0.26	4.66	8.64	8.27
EPS Growth	-98.69%	-	-46.10%	4.49%	-
Free Cash Flow	-116.08	-124.46	255.47	-53.61	-369.45
Free Cash Flow Per Share	-1.15	-1.25	5.90	-1.68	-11.54
Gross Margin	13.11%	16.57%	26.37%	29.67%	25.58%
Operating Margin	-4.66%	1.00%	12.17%	20.21%	16.55%
Profit Margin	1.09%	-2.30%	14.19%	19.80%	28.63%
Free Cash Flow Margin	-11.07%	-11.17%	17.96%	-3.84%	-39.98%
EBITDA	195.08	255.49	388.44	411.22	218.24
EBITDA Margin	18.60%	22.92%	27.31%	29.45%	23.61%
D&A For EBITDA	243.91	244.33	215.36	129	65.29
EBIT	-48.83	11.16	173.08	282.22	152.95
EBIT Margin	-4.66%	1.00%	12.17%	20.21%	16.55%
Effective Tax Rate	-	-	8.09%	9.93%	-

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.